Elisa Mariella

Elisa Mariella

Auto-generated profile, based on publicly available information

Elisa Mariella

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
MCMengnuo Chen
Mengnuo Chen
EMElisa Mariella
Elisa Mariella
HPHaoning Peng
Haoning Peng
SRSumaiyah K. Rehman
Sumaiyah K. Rehman
ABAlberto Bardelli
Alberto Bardelli

18 October 2016 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
EGElena Grassi
Elena Grassi
EMElisa Mariella
Elisa Mariella
ALAntonio Lembo
Antonio Lembo
IMivan molineris
ivan molineris
PPPaolo Provero
Paolo Provero
Background: Post-transcriptional regulation is a complex mechanism that plays a central role in defining multiple cellular identities starting from a common genome. Modifications in the length of 3’UTRs have been found to play an important role in this context, since alternative 3’ UTRs could lead to differences for example in regulation by microRNAs and cellular localization of the transcripts thus altering their fate. Results: We propose a strategy to identify the genes undergoing regulation of 3’ UTR length using RNA sequencing data obtained from standard libraries, thus widely applicable to data originally obtained to perform classical differential expression analyses. We decided to exploit previously annotated APA sites from public databases, in contrast with other approaches recently proposed in which the location of the APA site is inferred from the data together with the relative abundance of the isoforms. We demonstrate the reliability of our method by comparing it to the results of other microarray based or specific RNA-seq libraries methods and show that using APA sites databases results in higher sensitivity compared to de novo site prediction approach. Conclusions: We implemented the algorithm in a Bioconductor package to facilitate its broad usage in the scientific community. The ability of this approach to detect shortening from libraries with a number of reads comparable to that needed for differential expression analyses makes it useful for investigating if alternative polyadenylation is relevant in a certain biological process without requiring specific experimental assays.

26 July 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EDErika Durinikova
Erika Durinikova
NRNicole M. Reilly
Nicole M. Reilly
KBKristi Buzo
Kristi Buzo
EMElisa Mariella
Elisa Mariella
RCRosaria Chilà
Rosaria Chilà
SASabrina Arena
Sabrina Arena
Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. Experimental Design: We challenged 112 cell models recapitulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. Results: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unresponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phospho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated findings obtained in cell lines. Conclusions: In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.

16 August 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
EMElisa Mariella
Elisa Mariella
FMFederico Marotta
Federico Marotta
EGElena Grassi
Elena Grassi
SGStefano Gilotto
Stefano Gilotto
PPPaolo Provero
Paolo Provero
In the last decades, genome-wide association studies (GWAS) have uncovered tens of thousands of associations between common genetic variants and complex diseases. However, these statistical associations can rarely be interpreted functionally and mechanistically. As the majority of the disease-associated variants are located far from coding sequences, even the relevant gene is often unclear. A way to gain insight into the relevant mechanisms is to study the genetic determinants of intermediate molecular phenotypes, such as gene expression and transcript structure. We propose a computational strategy to discover genetic variants affecting the relative expression of alternative 3′ untranslated region (UTR) isoforms, generated through alternative polyadenylation, a widespread posttranscriptional regulatory mechanism known to have relevant functional consequences. When applied to a large dataset in which whole genome and RNA sequencing data are available for 373 European individuals, 2,530 genes with alternative polyadenylation quantitative trait loci (apaQTL) were identified. We analyze and discuss possible mechanisms of action of these variants, and we show that they are significantly enriched in GWAS hits, in particular those concerning immune-related and neurological disorders. Our results point to an important role for genetically determined alternative polyadenylation in affecting predisposition to complex diseases, and suggest new ways to extract functional information from GWAS data.

11 March 2024 in Molecular Oncology
Verified
Journal Article
Open access
EMElisa Mariella
Elisa Mariella
GGGaia Grasso
Gaia Grasso
MMMartina Miotto
Martina Miotto
KBKristi Buzo
Kristi Buzo
NRNicole Megan Reilly
Nicole Megan Reilly
ABAlberto Bardelli
Alberto Bardelli
Multiple strategies are continuously being explored to expand the drug target repertoire in solid tumors. We devised a novel computational workflow for transcriptome‐wide gene expression outlier analysis that allows the systematic identification of both overexpression and underexpression events in cancer cells. Here, it was applied to expression values obtained through RNA sequencing in 226 colorectal cancer (CRC) cell lines that were also characterized by whole‐exome sequencing and microarray‐based DNA methylation profiling. We found cell models displaying an abnormally high or low expression level for 3533 and 965 genes, respectively. Gene expression abnormalities that have been previously associated with clinically relevant features of CRC cell lines were confirmed. Moreover, by integrating multi‐omics data, we identified both genetic and epigenetic alternations underlying outlier expression values. Importantly, our atlas of CRC gene expression outliers can guide the discovery of novel drug targets and biomarkers. As a proof of concept, we found that CRC cell lines lacking expression of the MTAP gene are sensitive to treatment with a PRMT5‐MTA inhibitor (MRTX1719). Finally, other tumor types may also benefit from this approach.

3 November 2017 in Human Genetics
Verified
Journal Article
Closed access
PDF file
EGElena Grassi
Elena Grassi
EMElisa Mariella
Elisa Mariella
MFMattia Forneris
Mattia Forneris
FMFederico Marotta
Federico Marotta
MCMarika Catapano
Marika Catapano
PPPaolo Provero
Paolo Provero